

PERSONAL DATA

Name, first name Thumann, Gabriele
 Professional address Département des Neurosciences Cliniques
 Service d'Ophtalmologie
 Hôpitaux Universitaires de Genève
 Rue Alcide-Jentzer 22
 CH-1211 Genève 14

Contact Telephone: +41 (0)22 372 83 94
 Email: gabriele.thumann@hcuge.ch
 gabriele.thumann@unige.ch

Languages French (fluent), English (fluent), German (first language)



CURRENT POSITION Head of the Department of Ophthalmology, Geneva University Hospitals (HUG), Geneva, CH

PROFESSIONAL BACKGROUND

2015-Present Head of the Dept. of Ophthalmology, HUG, Geneva, CH

2014-2015 Head of the Dept. of Ophthalmology *ad interim*, HUG, Geneva, CH

2013-2014 Deputy Head of the Dept. of Ophthalmology, HUG, Geneva, CH (Head: Prof. Dr. med. F. Hafezi)

2012-2014 Head of the Unit of Vitreoretinal Surgery, HUG, Geneva, CH (Head: Prof. Dr. med. F. Hafezi)

2012-2018 Coordinator of the EU FP7 grant "TargetAMD", consortium of 13 partners

2012-Present Research Group Leader of Experimental Ophthalmology, UNIGE, Geneva, CH

2012-Present Full Professor of the Medical Faculty, Dept. of clinical Neurosciences, UNIGE, Geneva, CH

2009-2012 Member of the Directors' Board, The Aachen Center of Technology Transfer in Ophthalmology, RWTH Aachen University, Aachen, DE

2009-2012 Full Professor of the Medical Faculty, Dept. of Ophthalmology, Group Leader of Experimental Ophthalmology, RWTH Aachen University, Aachen, DE (Head: Prof. Dr. med. P. Walter)

2007-2012 Director of the Central Research Laboratories, Interdisciplinary Center of Clinical Research (IZKF), RWTH Aachen University, Aachen, DE

2006-2012 Member of the Directors' Board, IZKF, RWTH Aachen University, Aachen, DE

2006-2012 Research Group Leader and Consultant, Dept. of Ophthalmology, RWTH Aachen University, Aachen, DE (Head: Prof. Dr. med. P. Walter)

2006-2012 Chief resident, Dept. of Ophthalmology, RWTH Aachen University, Aachen, DE (Head: Prof. Dr. med. P. Walter)

2005-2006 Clinical Fellow, Anterior Segment and Glaucoma, Dept. of Ophthalmology, University of Cologne, Cologne, DE (Head: Prof. Dr. med. B. Kirchhof)

2004-2006 Deputy of the Head of the Unit of the Posterior Segment, University of Cologne, Cologne, DE (Head: Prof. Dr. med. B. Kirchhof)

2003-2006 Chief resident, Unit of the Posterior Segment and Vitreoretinal Surgery, Dept. of Ophthalmology, University of Cologne, Cologne, DE (Head: Prof. Dr. med. B. Kirchhof)

2001-2003 Clinical Fellow, Vitreoretinal Surgery, Dept. of Ophthalmology, University of Cologne, Cologne, DE (Head: Prof. Dr. med. G.K. Kriegelstein)

2001-2002 Specialist, Dept. of Ophthalmology, University of Cologne, Cologne, DE (Head: Prof. Dr. med. G.K. Kriegelstein)

1999-2001 Research Fellow with a DFG (*Deutsche Forschungsgemeinschaft*) grant to prepare the university habilitation, Laboratory of Cell and Molecular Biology, Dept. of Ophthalmology, University of Cologne, Cologne, DE (Head: Prof. Dr. med. G.K. Kriegelstein)

1997-1999 Research Fellow with a DFG research grant, Doheny Eye Institute, University of Southern California, Los Angeles, California, USA (Head: Prof. S.J. Ryan, MD)

1992-1997 Resident, Dept. of Ophthalmology, University of Cologne, Cologne, DE (Head: Prof. Dr. med. G.K. Kriegelstein)

DIPLOMA

2017	Fellow of the European Board of Ophthalmology (FEBO)
2014	Recognition as specialist in ophthalmic surgery, Berne, CH
2012	Recognition as specialist in ophthalmology, Berne, CH
2012	Recognition of medical diploma, Berne, CH
2001	University habilitation: "Transplantation of iris pigment epithelial cells to substitute for retinal pigment epithelial cells in age-related macular degeneration". University of Cologne, Cologne, DE (Head: Prof. Dr. med. G.K. Krieglstein)
1997	Specialist in ophthalmology, Düsseldorf, DE
1994	MD thesis: "Hepatic Surgery in children", University of Cologne, Cologne, DE
1994	License to practice medicine (<i>Approbation</i>), University of Cologne, Cologne, DE

UNDER-GRADUATE TRAINING

1988-1992	Studies in ophthalmology, Paris VI University, Hôpital des Quinze-Vingts, Paris, FR Studies in ophthalmic surgery, Paris V and VI Universities, Paris, FR Studies in internal medicine, NYU Medical School, New York, USA Studies in cardiology and intensive care, Paris XII University, Hôpital Henri Mondor, Paris, FR Studies in neonatology, Jackson Memorial Hospital, and studies in ophthalmology, Bascom Palmer Eye Institute, University of Miami, Miami, USA
1990-1991	Medical School, University of Cologne, Cologne, DE
1989-1990	Medical School, Paris XIII University, Paris, FR
1985-1989	Medical School, University of Cologne, Cologne, DE

DISTINCTIONS AND AWARDS

August 2019	J Lloyd Hewett Outstanding Paper Award for the paper "Duncan JL, Richards TP, Arditi A, da Cruz L, Dagnelie G, Dorn JD, Ho AC, de Koo LCO, Barale PO, Stanga PE, Thumann G, Wang Y, Greenberg RJ: Improvements in vision-related quality of life in blind patients implanted with the Argus II Epiretinal Prosthesis. Clin Exp Optom 2017, 100(2):144-150"
August 2013	Nomination as Full Professor and Head of the Dept. of Ophthalmology, University of Würzburg, Würzburg, DE, <i>primo unico loco</i> (refused in Jan. 2014)
August 2012	Nomination as Full Professor of the Medical Faculty, UNIGE, Geneva, CH (accepted in Sep. 2012)
November 2010	2 nd place in the nomination procedure as Full Professor and Head of the Dept. of Ophthalmology, Heinrich-Heine University Dusseldorf, Dusseldorf, DE
October 2008	Nomination as Full Professor of Experimental Ophthalmology, RWTH Aachen University, Aachen, DE (accepted in Mar. 2009)
April 2008	Nomination as Head of the Dept. of Ophthalmology, Pius Hospital, Georg-August-Universität Göttingen, Göttingen, DE (refused in Aug. 2008)

TEACHING

2012-present	Lectures, seminars and practical classes for medical students, residents' training, and continuous medical training at the UNIGE, Geneva, CH
2006-2012	Lectures, seminars and practical classes for medical students, residents' training, and continuous medical training at the RWTH University Aachen, Aachen, DE
1992-2006	Lectures, seminars and practical classes for medical students, residents' training, and continuous medical training at the University of Cologne, Cologne, DE

POST-GRADUATE SUPERVISION (1992-PRESENT)

Supervision of 15 MD theses:

Ms Isabel Llopis	UNIGE	ongoing
Ms Anna Schröter	UNIGE	ongoing
Mr. Filip Slezak	UNIGE	ongoing
Mr. Andrea Maccari	UNIGE	ongoing
Ms Eleonora Riggio	UNIGE	ongoing
Mr. Robin van Verlooven	UNIGE	ongoing
Mr. Mateusz Kecik	UNIGE	ongoing
Ms Laura Schwerm	RWTH Aachen University	ongoing

Dr. Theresa Hubert	RWTH Aachen University	2021
Dr. Stéphan Tobalem	UNIGE	2021
Dr. Paul Bertram	RWTH Aachen University	2018
Dr. Shuwei Tian	UNIGE	2017
Dr. Katharina Morawa	RWTH Aachen University	2017
Dr. David Kürten	RWTH Aachen University	2016
Dr. Marion Meier	RWTH Aachen University	2016

Supervision of 1 MD-PhD thesis:

Dr. Arthur Hammer	UNIGE	2017
--------------------------	-------	------

Supervision of 3 PhD theses:

Dr. Nina Harmening	RWTH Aachen University	2016
Dr. Christine Haselier	RWTH Aachen University	2016
Dr. Anna Salz	RWTH Aachen University	2010

UNDER-GRADUATE SUPERVISION (1992-PRESENT)

Supervision of 4 Master works in life sciences and 1 Master work in medicine:

Mr. Mohit	UNIGE	ongoing
Mr. Trong-Tin Kevin Steve Vo	UNIGE	2022
Mr. Nathan Breuillard	UNIGE	2022
Ms Hajer Zedira	Grenoble-Alpes University	2019
Ms Christina Leroy-Ciocanea	Sorbonne University - Paris VI University	2016

Co-supervision of 2 Master works in medicine

Ms Idil Oezsahin	UNIGE	2022
Mr. Maximiliano Giro Larraz	UNIGE	2021

SOCIETIES

DOG, ARVO, Nordrhein-Westfälische Gesellschaft für Ophthalmologie, Club Jules Gonin, DRG, SOF, SSO, ESGCT, SSPH

SCIENTIFIC ADVISORY BOARDS

B Braun, USA (Rheophoresis in AMD); Cell Cure Neurosci Ltd., Israel (Human embryonic stem cell transplantation); DSM Biomedical

APPOINTED REVIEWER

2021-2022	European Commission, Horizon programme, domaine "HORIZON-HLTH- 2021-DISEASE-04-04: Clinical validation of artificial intelligence (AI) solutions for treatment and care"
2021	Expert committee about medical devices, Euretina
2020-present	Swissmedic Medicines Expert Committee, Swissmedic, Berne, CH,
2012-present	Representative of the Dept. of <i>Neurosciences Cliniques</i> in the <i>Conseil Participatif</i> , UNIGE, Geneva, CH
2014	Swiss National Science Foundation (SNSF), Division Biology and Medicine
2015-2017	European Commission, Horizon 2020 programme, Area "Health, demographic change and well-being"

REVIEWER

Acta Ophthalmol (Copenhagen), Ann Anat, Biomaterials, Br J Ophthalmol, Clin Ophthalmol, Curr Eye Res, Graefes Arch Clin Exp Ophthalmol, IOVS, Ophthalmic Res, Langmuir, Prog Retin Eye Res

EDITOR

Current Genomics, Rare Disease and Orphan Drugs Journal, Biomedicines

FUNDING (1997-2021)

TOTAL = **11'048'816,14 CHF**

Funding > 100'000 CHF within the period:

- Haas foundation**, "Incubateur pour la co-culture de cellules oculaires et de rétine sans utilisation de produits d'animaux, comme modèle pour tester l'efficacité et la toxicité des thérapies innovantes pour traiter la DMLA" and "Thérapie génique non-virale basée sur les cellules souches pour traiter la DMLA sèche avancée", private funding 174'197 CHF
- SNSF**, grant no. 310030_189341/1, 2019-2023, "Integrative, transposon-based vectors in ocular gene therapy – safety improvement and in-process quality control", national funding 572'000 CHF
- ProVisu Foundation**, 2017, "Funding of the clinical trial TargetAMD_IPE", and "Persistence of efficacy of tIPE: a validated GMP-grade cell-based gene therapy product to treat neovascular AMD, proved using high-sensitivity methods", private funding 400'000 CHF

4. **SNSF**, grant no. 31003A_160195/1, 2015-2018, "Transposon-based gene cell therapy in the treatment of dry macular degeneration", national funding 474'000 CHF
5. **FRM**, (*Fondation pour la Recherche Médicale*), 2014, private funding 200'000 CHF
6. **EU FP7**, grant no. 305134, 2012-2018, "Transposon-Based, Targeted *Ex Vivo* Gene Therapy to Treat Age-Related Macular Degeneration (AMD)", coordinated by Prof. Thumann (total budget 5.9 Mio EURO), international funding 1'869'653 CHF
7. **DSM Biomedical B.V.**, 2012–2013, "*In vivo* Ophthalmic Degradation and Biocompatibility of implanted PEA fibrils and PTE biomaterials", industrial funding 157'795 CHF
8. **DFG**, grant no. Paketantrag PAK 469/1, 2011-2014, TH 303/15-1, 2011-2014, "Bidirektionelle Netzhautstimulation (Teilantrag C)", national funding 308'273 CHF
9. **IZKF**, 2006-2012, "Regeneration of ocular tissue using biohybrid implants and modulation of extracellular matrix", institutional funding (RWTH Aachen University) 2'168'318 CHF
10. **Resorba Wound Care**, 2006-2007, "Corneal and subretinal transplantation of tissue engineered collagen-based constructs", industrial funding 106'226 CHF
11. **Viscofan Bioengineering**, 2009-2010, "Biocompatibility of bone collagen membranes for ocular implantation", contract with Naturin Viscofan Ltd., industrial funding 151'125 CHF
12. **Spintec Engineering**, 2008-2009, industrial funding 196'025 CHF
13. **DE Ministry of Economy & Technology**, 2009-2011, "Silk membranes as temporary prosthesis for corneal wounds", national funding 183'978 CHF
14. **BMWi ZIM**, 2009-2011, national funding 178'065 CHF
15. **Fonds Castier**, institutional funding (HUG) TOTAL = 2'421'338 CHF
24 projects, 2015-2020 from 14'482 to 310'000 CHF
16. **Fondation pour la Recherche Médicale, 2012, « DEVELOP ME8955 »**, private funding 200'000 CHF
17. **Fondation privée des HUG**, institutional funding (HUG) TOTAL = 508'050 CHF
4 projects, 2014-2016 from 28'000 to 140'000 CHF
18. **Donations** TOTAL = 197'145 CHF

PATENTS (co-inventor)

- Patent pending "Methods and compositions for improving eye health", US No: 10,780,068.
- Patent pending "Methods and composition for diagnosing and treating glaucoma", Continuation-in-part of the above application, No: 16/938, 628 and PCT / US2018 / 030988.
- February 2001 "Pigment epithelial cell of the eye, its production and use in therapy of an eye or CNS disease", DE No: 21.02.01 / DEA 101 084 12; US No: 22.02.01 / USP 270746.

LIST OF PUBLICATIONS (1995-2022)*(As listed in Web of Science with 53 additional publications and 15 invited talks)*

Citation Report (Web of Science)

Number of articles in total	198
Number of total citations	2215
Number of total citations without auto-citations	2023
H Index	28

Peer reviewed articles

- Ramke J, Evans JR, Habtamu E, Mwangi N, Silva JC, Swenor BK, Congdon N, Faal HB, Foster A, Friedman DS, Gichuhi S, Jonas JB, Khaw PT, Kyari F, Murthy GVS, Wang N, Wong TY, Wormald R, Yusufu M, Taylor H, Resnikoff S, West SK, Burton MJ; **Grand Challenges in Global Eye Health study group**²: Grand Challenges in global eye health: a global prioritisation process using Delphi method. *Lancet Healthy Longev.* 2022 Jan, 3(1):e31-e41. doi: 10.1016/S2666-7568(21)00302-0. [IF 26.763]
- Bascuas T, Zedira H, Kropp M, Harmening N, Asrih M, Prat-Souteyrand C, Tian S, **Thumann G**: Human retinal pigment epithelial cells overexpressing the neuroprotective factors PEDF and GM-CSF to treat retinal neurodegeneration. *Current Gene Therapy* 2022, 22(2):168-183. DOI: 10.2174/1566523221666210707123809. [IF 4.391]
- Kecik M, Prod'hom S, Giannotti F, **Thumann G**, Malclès A: Simultaneous intraocular and orbital involvement of NK/T-cell lymphoma. *J Fr Ophtalmol* 2021, 44(10):e.595. [IF 0.818]
- Kecik M, Pajic B, Le Quoy O, **Thumann G**, Massa H: The SWISS IOL Technique (Small-Width Incision Scleral Suture): A Mini-Invasive Technique. *J Ophthalmol* 2021, 21(3):ID 8448996. [IF 1.909]
- Vasseneix C, Najjar RP, Xu X, Tang Z, Loo JL, Singhal S, Tow S, Milea L; Ting D S W SW, Liu Y, Wong TY, Newman NJ, Biousse V, Milea D, BONSAI group, **Thumann G**¹: Accuracy of a Deep Learning System for Classification of Papilledema Severity on Ocular Fundus Photographs. *Neurology* 2021, 97(4):e369-e377. [IF 9.910]
- Solomos L, Bouthour W, Malclès A, **Thumann G**, Massa H: Meibomian gland dysfunction: Intense pulse light therapy in combination with low-level light therapy as rescue treatment. *Medicina* 2021, 57(6):619. [IF 2.430]
- Tobalem* S , Kecik* M, Midroit M, Scaldino D, Tardy S, Bascuas T, Harmening N, Scapozza L, **Thumann G**, Kropp M: Functional and anatomical characterization of atrophic Age-related macular degeneration in an aged mouse model. *J Ophthalmol & Res* 2021, 4(2):128-152. [IF 1.200]
- Thumann G**, Sorgente N. AQP-9, KCNJ11 and ABCC8 gene variants in open angle glaucoma: A hypothesis. *J Ophthalmol & Res* 2021, 4(2):161-173. [IF 1.200]
- Thumann G**, Sorgente N, Kropp M, Jonescu-Cuypers C: Tolbutamide eye drops increase aqueous humor outflow and lower intraocular pressure: A proof of concept for glaucoma treatment. *J Ophthalmol & Res* 2021, 4(2):114-127. [IF 1.200]
- Johnen S, Harmening N, Marie C, Scherman D, Izsvák Z, Ivics Z, Walter P, **Thumann G**: Electroporation-based genetic modification of primary human pigment epithelial cells using the sleeping beauty transposon system. *JoVE* 2021, Feb 4, 168:e61987, doi: 10.3791/61987. [IF 1.355]
- Bascuas* T, Kropp* M, Harmening N, Wong BM, Johnen S, Izsvák Z, **Thumann G**: Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy. *JoVE* 2021, Feb. 26, 168:p. e62145, doi:10.3791/62145. [IF 1.355]
- Schroeter A, Kropp M, Cvejic Z, **Thumann G**, Pajic B: Comparison of femtosecond laser-assisted and ultrasound-assisted cataract surgery with focus on endothelial analysis. *Sensors* 2021, 21(3):996-1013. [IF 3.576]
- Bascuas T, Kropp M, Harmening N, Asrih M, Izsvák Z, **Thumann G**: Induction and analysis of oxidative stress in sleeping beauty transposon-transfected human retinal pigment epithelial cells. *JoVE* 2020, Dec 11, 166: doi: 10.3791/61957. [IF 1.355]
- Biousse V, Newman NJ, Najjar RP, Vasseneix C, Xu X, Ting DS, Milea LB, Hwang JM, Kim DH, Yang HK, Hamann S, Chen JJ, Liu Y, Wong TY, Milea D, BONSAI Study Group, **Thumann G**¹: Optic Disc Classification by Deep Learning versus Expert Neuro-Ophthalmologists. *Ann Neurol* 2020, 88: 785–795. [IF 10.422]
- Milea D, Najjar RP, Zhuho J, Ting D, Vasseneix C, Xu X, Aghsaei Fard M, Fonseca P, Vanikieti K, Lagrèze WA, La Morgia C, Cheung CY, Hamann S, Chiquet C, Sanda N, Yang H, Mejico LJ, Rougier M-B, Kho R, Thi Ha Chau T, Singhal S, Gohier P, Clermont-Vignal C, Cheng C-Y, Jonas JB, Yu-Wai-Man P, Fraser CL, Chen JJ, Ambika S, Miller NR, Liu Y, Newman NJ, Wong TY, Biousse V, BONSAI Group, **Thumann G**¹: Artificial Intelligence to Detect Papilledema from Ocular Fundus Photographs. *N Engl J Med* 2020, 382(18):1687-1695. [IF 91.245]

16. Tobalem S, Weinberger A, Kropp M, Malcès A, Jonescu-Cuypers C, Souteyrand G, **Thumann G**: Chorioretinal toxicity of the perfluorooctane ALA® OCTA: Results from 48 surgical procedures in Geneva. *Am J Ophthalmol* 2020, 218:28-39. [IF 5.258]
17. Keis AJ, Guirou N, Coulibaly S, Bakayoko S, Sugnanam K, Jonescu-Cuypers C, **Thumann G**, Resnikoff S, Solomon AW: Challenges in addressing post-operative trichomatous trichiasis. *Eye (Lond)* 2020, 34(11):2131-2132. [IF 3.775]
18. Rbaux PG, Britan A, **Thumann G**, Delie Salmon F, Petignat P, Cohen M-B: Malignant ascites: a source of therapeutic protein against ovarian cancer? *Oncotarget* 2019, 10(57):5894-5905. [IF 5.168]
19. Hernandez M, Recalde S, Garcia-Garcia L, Bezunartea J, Miskey C, Johnen S, Diarra S, Sebe A, Rodriguez-Madoz JR, Pouillot S, Marie C, Izsvák Z, Scherman D, Kropp M, Prosper F, **Thumann G**, Ivics Z, Garcia-Layana A, Fernandez-Robredo P: Preclinical Evaluation of a Cell-Based Gene Therapy Using the Sleeping Beauty Transposon System in Choroidal Neovascularization. *Mol Ther Methods Clin Dev* 2019, 15:403-417. [IF 6.698]
20. Cnsigli A, Papanastasiou A, Roquelaure D, Wuarin R, Roy S, **Thumann G**, Chronopoulos A: Changes in Retinal Vascular Caliber after Intravitreal Aflibercept Treatment for Diabetic Macular Oedema. *Klin Monatsbl Augenheilkd* 2019, 236(11):1318-1324. [IF 0.700]
21. Prod'hom S, Weinberger A, **Thumann G**, Malcès A: Lipemia retinalis: contribution of ultra-widefield imaging and spectral domain OCT. *J Fr Ophthalmol* 2019, 42(8):940-943. [IF 0.818]
22. Villard F, **Thumann G**, Malcès A: Bilateral Loss of Vision a Few Hours After a Motor Vehicle Crash. *JAMA Ophthalmol* 2019, 137(9):1080-1081. [IF 7.389]
23. Warin R, Kakkassery V, Consigli A, Roquelaure D, Papanastasiou A, Schutz JS, **Thumann G**, Chronopoulos A: Combined Topical Anti-inflammatory and Oral Acetazolamide in the Treatment of Central Serious Chorioretinopathy. *Optom Vis Sci* 2019, 96(7):500-506. [IF 1.973]
24. Correia M, Brunner D, Sharma M, Andrade V, Magno J, Muller A, Pereira BM, **Thumann G**, Verma N, Bangert M, Kreis AJ, Solomon AW: A search for trachoma in Timor-Leste: no evidence to justify undertaking population-based prevalence surveys. *Ophthalmic Epidemiol* 2018, 25:131-137. [IF 1.648]
25. Pastor M, Johnen S, Harmening N, Quiviger M, Pailloux J, Kropp M, Walter P, Ivics Z, Izsvák Z, **Thumann G**, Scherman D, Marie C: The Antibiotic-free pFAR4 Vector Paired with the Sleeping Beauty Transposon System Mediates Efficient Transgene Delivery in Human Cells. *Mol Ther Nucleic Acids* 2018, 11:57-67. [IF 8.886]
26. Hselier C, Biswas S, Rosch S, **Thumann G**, Muller F, Walter P: Correlations between specific patterns of spontaneous activity and stimulation efficiency in degenerated retina. *PLoS One* 2017, 12(12):16. [IF 3.240]
27. Garcia-Garcia L, Recalde S, Hernandez M, Bezunartea J, Rodriguez-Madoz JR, Johnen S, Diarra S, Marie C, Izsvák Z, Ivics Z, Scherman D, Kropp M, **Thumann G**, Prosper F, Fernandez-Robredo P, Garcia-Layana A: Long-Term PEDF Release in Rat Iris and Retinal Epithelial Cells after Sleeping Beauty Transposon-Mediated Gene Delivery. *Mol Ther Nucleic Acids* 2017, 9:1-11. [IF 8.886]
28. Jcquier P, Massa H, Chronopoulos A, **Thumann G**, Souteyrand G: Vitreous hemorrhage, persistent fetal vasculature and Incontinentia Pigmenti. *J Fr Ophthalmol* 2017, 40(10):E397-E399. [IF 0.818]
29. Jcquier P, Wuarin R, Chizzolini C, **Thumann G**, Steffen H, Chronopoulos A: Case Report: Masquerading Large-vessel Giant Cell Arteritis. *Optom Vis Sci* 2017, 94(12):1159-1164. [IF 1.973]
30. Atheriou MC, Malcès A, Spinelli A, **Thumann G**: Corneal complications of a case of vernal keratoconjunctivitis. *J Fr Ophthalmol* 2017, 40(8):719-720. [IF 0.818]
31. Chronopoulos A, Hoogewoud F, Steffen H, **Thumann G**: Parainfectious optic neuritis with macular infiltrate in Neisseria meningitidis B meningitis. *Ophthalmologie* 2017, 114(10):945-949. [IF 1.059]
32. Tobalem S, **Thumann G**, Chronopoulos A: Uncomplicated massive central retinal artery embolism. *J Fr Ophthalmol* 2017, 40(4):345-345. [IF 0.818]
33. **Thumann G**, Harmening N, Prat-Souteyrand C, Marie C, Pastor M, Sebe A, Miskey C, Hurst LD, Diarra S, Kropp M, Walter P, Scherman D, Ivics Z, Izsvák Z, Johnen S: Engineering of PEDF-Expressing Primary Pigment Epithelial Cells by the SB Transposon System Delivered by pFAR4 Plasmids. *Mol Ther Nucl Acids* 2017, 6:302-314. [IF 8.886]
34. Duncan JL, Richards TP, Arditi A, da Cruz L, Dagnelie G, Dorn JD, Ho AC, de Koo LCO, Barale PO, Stanga PE, **Thumann G**, Wang YZ, Greenberg RJ: Improvements in vision-related quality of life in blind patients implanted with the Argus II Epiretinal Prosthesis. *Clin Exp Optom* 2017, 100(2):144-150. [IF 2.742]
35. Dagnelie G, Christopher P, Arditi A, da Cruz L, Duncan JL, Ho AC, de Koo LCO, Sahel JA, Stanga PE, **Thumann G**, Wang YZ, Arsiero M, Dorn JD, Greenberg RJ, Argus II Study Groupe: Performance of real-world functional vision tasks by blind subjects improves after implantation with the Argus® II retinal prosthesis system. *Clin Exp Ophthalmol* 2017, 45(2):152-159. [IF 4.207]
36. De Massougnes S, Malcès A, Souteyrand G, Massa H, **Thumann G**, Steffen H: Retinal astrocytic hamartoma: Multimodal imaging. *J Fr Ophthalmol* 2017, 40(1):84-86. [IF 0.818]
37. Chronopoulos A, Roquelaure D, Souteyrand G, Seebach JD, Schutz JS, **Thumann G**: Aqueous humor polymerase chain reaction in uveitis - utility and safety. *BMC Ophthalmol* 2016, 16:7. [IF 2.209]

38. Rquelaure D, Harbarth S, Schutz JS, **Thumann G**, Chronopoulos A: Epstein-Barr virus associated acute retinal necrosis. *Ophthalmologie* 2016, 113(10):864-866. [IF 1.059]
39. Gruschat DR, Richards TP, Arditi A, da Cruz L, Dagnelie G, Dorn JD, Duncan JL, Ho AC, de Koo LCO, Sahel JA, Stanga PE, **Thumann G**, Wang VZ, Greenberg RJ: An analysis of observer-rated functional vision in patients implanted with the Argus II Retinal Prosthesis System at three years. *Clin Exp Optom* 2016, 99(3):227-232. [IF 2.742]
40. Chronopoulos A, Roquelaure D, Jacquier P, Souteyrand G, Matter M, **Thumann G**: The management of diabetic retinopathy and diabetic macular edema; joint forces fight for sight. *RMS* 2015, 11(499):2381-2387. [IF 0.130]
41. Souteyrand G, Chronopoulos A, **Thumann G**: Drug-induced toxicity and ophthalmology. *RMS* 2015, 11(499):2374-2380. [IF 0.130]
42. Bhar-Cohen F, **Thumann G**: L'œil, aux carrefours de l'humain. *RMS* 2015, 11(499):2359. [IF 0.130]
43. Cnsigli A, Roquelaure D, Souteyrand G, Chizzolini C, **Thumann G**, Chronopoulos A: Diagnostic Dilemma in Sequential Branch Retinal Vein and Artery Occlusion. *Optom Vis Sci* 2015, 92(11):E404-E408. [IF 1.973]
44. Mittal R, **Thumann G**, Souteyrand G, Kuerten D, Coupland SE: Retinochoroidal toxoplasmosis in a patient with cerebral post-transplant lympho-proliferative disease of Hodgkin's type: a diagnostic challenge. *J Ophthal Inflamm Infect* 2015, 5:4. [Cite score 2.500]
45. Kuerten D, Johnen S, Harmening N, Souteyrand G, Walter P, **Thumann G**: Transplantation of PEDF-transfected pigment epithelial cells inhibits corneal neovascularization in a rabbit model. *Graefes Arch Clin Exp Ophthalmol* 2015, 253(7):1061-1069. [IF 3.117]
46. **Thumann G**, Perdikomati-Dahmen M, Izsvák Z, Ivics Z, Garcia-Layana A, Ronchetti M, Petrovski G, Scherman D, Aranda P, Pouillot S, Binder S, Johnen S, Van den Berg J, TargetAMD Consortium: Transposon-Based, Targeted Ex Vivo Gene Therapy to Treat Age-Related Macular Degeneration (TargetAMD). *Hum Gene Ther Clin Dev* 2015, 26(2):97-100. [IF 5.032]
47. Chronopoulos A, Varga Z, Steinfeld PA, Dahlmann R, Jukic T, Walter P, **Thumann G**: Unusual IOL Calcification following Vitreoretinal Surgery with Silicone Oil Endotamponade. *Klin Monatsbl Augenheilkd.* 2015, 232(6):779-784. [IF 0.700]
48. Johnen S, Djalali-Talab Y, Kazanskaya O, Moller T, Harmening N, Kropp M, Izsvák Z, Walter P, **Thumann G**: Antiangiogenic and Neurogenic Activities of Sleeping Beauty-Mediated PEDF-Transfected RPE Cells In Vitro and In Vivo. *Biomed Res Int* 2015, 2015:ID 863845. [IF 3.411]
49. Chronopoulos A, Lipski A, Jonescu-Cuyers CP, **Thumann G**: Unusual bilateral traumatic maculopathy following whiplash injury. *BMJ Case Rep* 2014, 2014:bcr-2014208068.
50. Bswas S, Haselier C, Mataruga A, **Thumann G**, Walter P, Muller F: Pharmacological Analysis of Intrinsic Neuronal Oscillations in rd10 Retina. *PLoS One* 2014, 9(6):13. [IF 3.240]
51. Waschkowski F, Hesse S, Rieck AC, Lohmann T, Brockmann C, Laube T, Bornfeld N, **Thumann G**, Walter P, Mokwa W, Johnen S, Roessler G: Development of very large electrode arrays for epiretinal stimulation (VLARS). *Biomed Eng Online* 2014, 13:15. [IF 2.819]
52. Kopp M, Morawa KM, Mihov G, Salz AK, Harmening N, Franken A, Kemp A, Dias AA, Thies J, Johnen S, **Thumann G**: Biocompatibility of Poly(ester amide) (PEA) Microfibrils in Ocular Tissues. *Polymers* 2014, 6(1):243-260. [IF 4.329]
53. Pnos GD, Gatzoufas Z, Petropoulos IK, Dardabounis D, **Thumann G**, Hafezi F: Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration. *Drug Des Dev Ther* 2013, 7:565-569. [IF 4.162]
54. Koutsonas A, Carstesen D, Henkel C, Walter P, **Thumann G**, Weinberger AWA: Effects of Coagulation on the Autofluorescence Pattern of ARPE-19 Cells: An in vitro Study. *Ophthalmic Res* 2013, 49(1):11-19. [IF 2.892]
55. Johnen S, Izsvák Z, Stocker M, Harmening N, Salz AK, Walter P, **Thumann G**: Sleeping Beauty Transposon-Mediated Transfection of Retinal and Iris Pigment Epithelial Cells. *IOVS* 2012, 53(8):4787-4796. [IF 4.799]
56. **Thumann G**, Armogan N, Schwanz T, Gaebler A, Vehr A-K, Walter P, Mazinani B: Fulminant Postoperative Endophthalmitis due to Streptococcus Pneumoniae. *Klin Monatsbl Augenheilkd* 2011, 228(12):1108-1109. [IF 0.700]
57. Johnen S, Kazanskaya O, Armogan N, Stickelmann C, Stocker M, Walter P, **Thumann G**: Endogenous Regulation of Proliferation and Zinc Transporters by Pigment Epithelial Cells Nonvirally Transfected with PEDF. *IOVS* 2011, 52(8):5400-5407. [IF 4.799]
58. Jöres APW, Carstesen D, **Thumann G**, Walter P, Weinberger AWA: Detection of heat shock protein 70 in choroidal neovascular membranes secondary to age related macular degeneration. *BMC Research Notes* 2011, 4:115. DOI : 10.1186/1756-0500-4-115. [Impact Score 1.660]
59. Johnen S, Wickert L, Meier M, Salz AK, Walter P, **Thumann G**: Presence of Xenogenic Mouse RNA in RPE and IPE Cells Cultured on Mitotically Inhibited 3T3 Fibroblasts. *IOVS* 2011, 52(5):2817-2824. [IF 4.799]
60. Buzard K, Zhang JR, **Thumann G**, Stripecke R, Sunalp M: Two cases of toxic anterior segment syndrome from generic trypan blue. *J Cataract Refract Surg* 2010, 36(12):2195-2199. [IF 3.351]

61. **Thumann G**, Stocker M, Maltusch C, Salz AK, Barth S, Walter P, Johnen S: High efficiency non-viral transfection of retinal and iris pigment epithelial cells with pigment epithelium-derived factor. *Gene Ther* 2010, 17(2):181-189. [IF 5.250]
62. Jukic T, Katusic D, Kordic R, Cacic M, Braunschweig T, **Thumann G**: Malignant melanoma of the cornea after blunt trauma. *Ophthalmologe* 2009, 106(7):625-627. [IF 1.059]
63. **Thumann G**, Salz A, Walter P, Johnen S: Preservation of photoreceptors in dystrophic RCS rats following allo- and xenotransplantation of IPE cells. *Graefes Arch Clin Exp Ophthalmol* 2009, 247(3):363-369. [IF 3.117]
64. **Thumann G**, Viethen A, Gaebler A, Walter P, Kaempf S, Johnen S, Salz AK: The in vitro and in vivo behaviour of retinal pigment epithelial cells cultured on ultrathin collagen membranes. *Biomaterials* 2009, 30(3):287-294. [IF 12.479]
65. Kempf S, Walter P, Salz AK, **Thumann G**: Novel organotypic culture model of adult mammalian neurosensory retina in co-culture with retinal pigment epithelium. *J Neurosci Methods* 2008, 173(1):47-58. [IF 2.390]
66. Kempf S, Johnen S, Salz AK, Weinberger A, Walter P, **Thumann G**: Effects of bevacizumab (Avastin) on retinal cells in organotypic culture. *IOVS* 2008, 49(7):3164-3171. [IF 4.799]
67. Asenbrey S, Bartz-Schmidt KU, Walter P, Hilgers RD, Ayertey H, Szurman P, **Thumann G**: Long-term follow-up of macular translocation with 360 retinotomy for exudative age-related macular degeneration. *Arch Ophthalmol* 2007, 125(10):1367-1372. [IF 4.399]
68. Weinberger AWA, Thiel M, Mohammadi B, Theofylaktopoulos L, **Thumann G**, Walter P: Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. *Am J Ophthalmol* 2007, 144(2):294-296. [IF 5.258]
69. Surman P, Roters S, Grisanti S, Aisenbrey S, Schraermeyer U, Luke M, Bartz-Schmidt KU, **Thumann G**: Ultrastructural changes after artificial retinal detachment with modified retinal adhesion. *IOVS* 2006, 47(11):4983-4989. [IF 4.799]
70. Mnnel S, Peter S, Meyer CH, **Thumann G**: Effect of photodynamic therapy on the function of the outer blood-retinal barrier in an in vitro model. *Graefes Arch Clin Exp Ophthalmol* 2006, 244(8):1015-1021. [IF 3.117]
71. Mennel S, **Thumann G**, Peter S, Meyer CH, Kroll P: Influence of vital dyes on the function of the outer blood-retinal barrier in vitro. *Klin Monatsbl Augenheilkd* 2006, 223(7):568-576. [IF 0.700]
72. Dnslage S, Jordan JF, Roessler G, Esser J, Omran M, **Thumann G**, Wyen C, Hoppe T, Wohrmann A, Dietlein T, Krieglstein GK: Bilateral anterior panuveitis as early manifestation of syphilis in a patient with HIV infection. *Klin Monatsbl Augenheilkd* 2006, 223(6):538-541. [IF 0.700]
73. **Thumann G**, Hueber A, Dinslage S, Schaefer F, Yasukawa T, Kirchhof B, Yafai Y, Eichler W, Bringmann A, Wiedemann P: Characteristics of iris and retinal pigment epithelial cells cultured on collagen type I membranes. *Curr Eye Res* 2006, 31(3):241-249. [IF 2.424]
74. Asenbrey S, Lafaut BA, Szurman P, Hilgers RD, Esser P, Walter P, Bartz-Schmidt KU, **Thumann G**: Iris pigment epithelial translocation in the treatment of exudative macular degeneration - A 3-year follow-up. *Arch Ophthalmol* 2006, 124(2):183-188. [IF 4.399]
75. **Thumann G**, Aisenbrey S, Schaefer F, Bartz-Schmidt KU: Instrumentation and technique for delivery of tissue explants to the subretinal space. *Ophthalmologica* 2006, 220(3):170-173. [IF 3.250]
76. Lndwehr S, Kiencke P, Giesecke T, Eggert D, **Thumann G**, Kampe S: A comparison between IV paracetamol and IV metamizol for postoperative analgesia after retinal surgery. *Curr Med Res Opin* 2005, 21(10):1569-1575. [IF 2.580]
77. **Thumann G**, Kirchhof B: Transplantation of iris pigment epithelium. *Ophthalmologe* 2004, 101(9):882-885. [IF 1.059]
78. Abdel-Meguid A, Lappas A, Hartmann K, Auer F, Schrage N, **Thumann G**, Kirchhof B: One year follow up of macular translocation with 360 degree retinotomy in patients with age-related macular degeneration. *Br J Ophthalmol* 2003, 87(5):615-621. [IF 4.638]
79. Roters S, Szurman P, Hermes S, **Thumann G**, Bartz-Schmidt KU, Kirchhof B: Outcome of combined penetrating keratoplasty with vitreoretinal surgery for management of severe ocular injuries. *Retina* 2003, 23(1):48-56. [IF 4.256]
80. Roters S, Hamzei P, Szurman P, Hermes S, **Thumann G**, Bartz-Schmidt KU, Kirchhof B: Combined penetrating keratoplasty and vitreoretinal surgery with silicone oil: a 1-year follow-up. *Graefes Arch Clin Exp Ophthalmol* 2003, 241(1):24-33. [IF 3.117]
81. **Thumann G**: Potential of pigment epithelium transplantation in the treatment of AMD. *Graefes Arch Clin Exp Ophthalmol* 2002, 240(9):695-697. [IF 3.117]
82. Kciok N, Hueber A, Esser P, Schraermeyer U, **Thumann G**, Luther TT, Jordan J, Welsandt G, Kirchhof B: Vitreous treatment of cultured human RPE cells results in differential expression of 10 new genes. *IOVS* 2002, 43(7):2474-2480. [IF 4.799]
83. Aisenbrey S, Lafaut BA, Szurman P, Grisanti S, Luke C, Krott R, **Thumann G**, Fricke J, Neugebauer A, Hilgers RD, Esser P, Walter P, Bartz-Schmidt KU: Macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. *Arch Ophthalmol* 2002, 120(4):451-459. [IF 4.399]

84. Shraermeyer U, **Thumann G**, Luther T, Kociok N, Arnhold S, Kruttwig K, Andressen C, Addicks K, Bartz-Schmidt KU: Subretinally transplanted embryonic stem cells rescue photoreceptor cells from degeneration in the RCS rats. *Cell Transplant* 2001, 10(8):673-680. [IF 4.064]
85. Kayatz P, **Thumann G**, Luther TT, Jordan JF, Bartz-Schmidt KU, Esser PJ, Schraermeyer U: Oxidation causes melanin fluorescence. *IOVS* 2001, 42(1):241-246. [IF 4.799]
86. Shraermeyer U, Kayatz P, **Thumann G**, Luther TT, Szurman P, Kociok N, Bartz-Schmidt KU: Transplantation of iris pigment epithelium into the choroid slows down the degeneration of photoreceptors in the RCS rat. *Graefes Arch Clin Exp Ophthalmol* 2000, 238(12):979-984. [IF 3.117]
87. **Thumann G**, Aisenbrey S, Schraermeyer U, Lafaut B, Esser P, Walter P, Bartz-Schmidt KU: Transplantation of autologous iris pigment epithelium after removal of choroidal neovascular membranes. *Arch Ophthalmol* 2000, 118(10):1350-1355. [IF 4.399]
88. Ci JZ, Kimura H, Spee C, **Thumann G**, Hinton DR, Ryan SJ: Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate. *Graefes Arch Clin Exp Ophthalmol* 2000, 238(4):326-333. [IF 3.117]
89. **Thumann G**, Bartz-Schmidt KU, Kociok N, Heimann K, Schraermeyer U: Ultimate Fate of Rod Outer Segments in the Retinal Pigment Epithelium. *Pigment Cell Res* 1999, 12(5):311-315. [IF 4.288]
90. **Thumann G**, Bartz-Schmidt KU, Kociok N, Kayatz P, Heimann K, Schraermeyer U: Retinal damage by light in the golden hamster: an ultrastructural study in the retinal pigment epithelium and Bruch's membrane. *J Photochem Photobiol B* 1999, 49(2-3):104-111. [IF 6.252]
91. Bartz-Schmidt KU, **Thumann G**, Psichias A, Krieglstein GK, Heimann K: Pars plana vitrectomy, endolaser coagulation of the retina and the ciliary body combined with silicone oil endotamponade in the treatment of uncontrolled neovascular glaucoma. *Graefes Arch Clin Exp Ophthalmol* 1999, 237(12):969-975. [IF 3.117]
92. **Thumann G**, Kociok N, Bartz-Schmidt KU, Esser P, Schraermeyer U, Heimann K: Detection of mRNA for proteins involved in retinol metabolism in iris pigment epithelium. *Graefes Arch Clin Exp Ophthalmol* 1999, 237(12):1046-1051. [IF 3.117]
93. **Thumann G**, Bartz-Schmidt KU, El Bakri H, Schraermeyer U, Spee C, Cui JZ, Hinton DR, Ryan SJ, Heimann K: Transplantation of autologous iris pigment epithelium to the subretinal space in rabbits. *Transplantation* 1999, 68(2):195-201. [IF 4.939]
94. Jnescu-Cuyper CP, **Thumann G**, Hilgers RD, Bartz-Schmidt KU, Krott P, Krieglstein GK: Long-term fluctuations of the normalised rim/disc area ratio quotient in normal eyes. *Graefes Arch Clin Exp Ophthalmol* 1999, 237(3):181-186. [IF 3.117]
95. Shraermeyer U, Peters S, **Thumann G**, Kociok N, Heimann K: Melanin granules of retinal pigment epithelium are connected with the lysosomal degradation pathway. *Exp Eye Res* 1999, 68(2):237-245. [IF 3.467]
96. Psichias A, Bartz-Schmidt KU, **Thumann G**, Krieglstein GK, Heimann K: Vitreoretinal surgery in the treatment of neovascular glaucoma. *Klin Monatsbl Augenheilkd* 1999, 214(2):61-70. [IF 0.700]
97. Lke C, Bartz-Schmidt KU, Walter P, **Thumann G**, Brunner R, Michel O, Sickel W: Effects of etoposide (vp16) on vertebrate retinal function. *J Toxicol Cutaneous Ocul Toxicol* 1999, 18(1):23-32. [IF 0.407]
98. **Thumann G**, Bartz-Schmidt KU, Heimann K, Schraermeyer U: Phagocytosis of rod outer segments by human iris pigment epithelial cells in vitro. *Graefes Arch Clin Exp Ophthalmol* 1998, 236(10):753-757. [IF 3.117]
99. Kociok N, Heppekaussen H, Schraermeyer U, Esser P, **Thumann G**, Grisanti S, Heimann K: The mRNA expression of cytokines and their receptors in cultured iris pigment epithelial cells: A comparison with retinal pigment epithelial cells. *Exp Eye Res* 1998, 67(2):237-250. [IF 3.467]
100. **Thumann G**, Schraermeyer U, Bartz-Schmidt KU, Heimann K: Descemet's membrane as membranous support in RPE/IPE transplantation. *Curr Eye Res* 1997, 16(12):1236-1238. [IF 2.424]
101. **Thumann G**, Bartz-Schmidt KU, Esser P, Walter P, Kirchhof B, Krott R, Brunner R, Heimann K: Vitrectomy in the management of complicated uveitis. *Klin Monatsbl Augenheilkd* 1997, 211(4):241-244. [IF 0.700]
102. **Thumann G**, Bartz-Schmidt KU, Kirchhof B, Heimann K: Branch retinal artery occlusion by diathermy of a persistent hyaloid artery. *Am J Ophthalmol* 1997, 124(3):415-416. [IF 5.258]
103. Esser P, Heimann K, Bartz-Schmidt KU, Fontana A, Schraermeyer U, **Thumann G**, Weller M: Apoptosis in proliferative vitreoretinal disorders: Possible involvement of TGF-beta-induced RPE cell apoptosis. *Exp Eye Res* 1997, 65(3):365-378. [IF 3.467]
104. **Thumann G**, Kirchhof B, Bartz-Schmidt KU, Jnescu-Cuyper CP, Esser P, Konen W, Heimann K: The artificial iris diaphragm for vitreoretinal silicone oil surgery. *Retina* 1997, 17(4):330-337. [IF 4.256]
105. **Thumann G**, Baum UE, Bartz-Schmidt KU, Lanfermann H, Landwehr P, Esser P, Konen W: Risks and therapeutic options of dural AV-fistula of the arteria carotis externa and the sinus cavernosus. Case report and review of the literature. *Klin Monatsbl Augenheilkd* 1996, 209(6):AA10-AA13. [IF 0.700]
106. Bartz-Schmidt KU, Jnescu-Cuyper CP, **Thumann G**, Frucht J, Krieglstein GK: Influence of the contourline on the cup area using the Heidelberg Retina Tomograph. *Klin Monatsbl Augenheilkd* 1996, 209(5):292-297. [IF 0.700]

107. Bartz-Schmidt KU, Jonescu-Cuypers CP, **Thumann G**, Frucht J, Sengersdorf A, Hilgers RD, Krieglstein GK: The normalised rim disc area ratio line. *Int Ophthalmol* 1996, 19(6):331-335. [IF 2.031]

Review articles

108. Chronopoulos A, Ong JM, **Thumann G**, Schutz JS: Occult globe rupture: diagnostic and treatment challenge. *Surv Ophthalmol* 2018, 63(5):694-699. [IF 6.048]
109. Chronopoulos A, Herbert J, **Thumann G**, Schutz JS: Avoiding Complications From Patient Positioning for Intraocular Surgery. *Anesth Analg* 2018, 126(4):1206-1211. [IF 5.108]
110. Solba U, Ansari-Shahrezaei S, Hagen S, Staffin M, Schmid S, Kropp M, Harmening N, **Thumann G**, TargetAMD consortium: Neovascular age-related macular degeneration in Austria: Expert review and introduction to the TargetAMD approach. *Spektrum Augenheilkd* 2017, 31(5):206-211. [IF 0.177]
111. Chronopoulos A, **Thumann G**, Schutz J: Positive vitreous pressure: Pathophysiology, complications, prevention, and management. *Surv Ophthalmol* 2017, 62(2):127-133. [IF 6.048]
112. Hudecek M, Izsák Z, Johnen S, Renner M, **Thumann G**, Ivics Z: Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side. *Crit Rev Biochem Mol Biol* 2017, 52(4):355-380. [IF 8.250]
113. Hogewoud F, Chronopoulos A, Varga Z, Souteyrand G, **Thumann G**, Schutz JS: Traumatic retinal detachment - the difficulty and importance of correct diagnosis. *Surv Ophthalmol* 2016, 61(2):156-163. [IF 6.048]
114. Garcia-Layana A, **Thumann G**, Groll J: Age Macular Degeneration: Etiology, Prevention, Individualized Therapies, Cell Therapy, and Tissue Engineering. *J Ophthalmol* 2014:ID 287893. [IF 1.909]
115. Fernandez-Robredo P, Sancho A, Johnen S, Recalde S, Gama N, **Thumann G**, Groll J, Garcia-Layana A: Current Treatment Limitations in Age-Related Macular Degeneration and Future Approaches Based on Cell Therapy and Tissue Engineering. *J Ophthalmol* 2014:ID 510285. [IF 1.909]
116. **Thumann G**: Prospectives for Gene Therapy of Retinal Degenerations. *Curr Genomics* 2012, 13(5):350-362. [IF 2.236]
117. **Thumann G**: Nonviral gene therapy for age-related macular degeneration. *Expert Rev Ophthalmol* 2011, 6(1):81-93. [IF 0.980]
118. **Thumann G**, Walter P: Non-pharmacological interventional perspectives in AMD. *Klin Monatsbl Augenheilkd* 2008, 225(8):699-702. [IF 0.700]
119. **Thumann G**: Development and cellular functions of the iris pigment epithelium. *Surv Ophthalmol* 2001, 45(4):345-354. [IF 6.048]
120. Bartz-Schmidt KU, **Thumann G**, Jonescu-Cuypers CP, Krieglstein GK: Quantitative morphologic and functional evaluation of the optic nerve head in chronic open-angle glaucoma. *Surv Ophthalmol* 1999, 44:S41-S53. [IF 6.048]

Book Chapters

121. **Thumann G**, Dou G, Wang Y, Hinton DR: Cell Biology of the Retinal Pigment Epithelium. In: *Retina* (Fifth Edition). Edited by Ryan SJ, Sadda SR, Hinton DR, Schachat AP, Wilkinson CP, Wiedemann P, vol 1. London: WB Saunders; 2013: 401-414.
122. **Thumann G**, Hoffmann S, Hinton DR: Cell Biology of the Retinal Pigment Epithelium. In: *Retina* (Fourth Edition). Edited by Ryan SJ, Hinton DR, Schachat AP, Wilkinson CP, vol 1. Edinburgh: Mosby; 2006: 137-152.
123. **Thumann G**, Aisenbrey S, Bartz-Schmidt KU: Iris pigment epithelium transplantation — experimental and clinical results. In: *The Macula: Diagnosis, Treatment and Future Trends* (First Edition). Edited by Binder S. Wien: Springer-Verlag; 2004: 51-56.
124. Toth CA, **Thumann G**, Kirchhof B: Surgical Therapy. In: *Age-related macular degeneration*. Edited by Holz FG, Pauleikhoff D, Spaide RF. Berlin, Heidelberg: Springer Berlin Heidelberg; 2004: 169-187.
125. Kayatz P, **Thumann G**, Schraermeyer U: Ultrastructural localization of light-induced lipid peroxides. In: *Redox Cell Biology and Genetics Part A*. Edited by Sen C, Packer L, vol. 352. San Diego USA: Academic Press; 2002: 378-391.
126. Bartz-Schmidt KU, **Thumann G**: Bulbusberstung (Ruptur). In: *Ophthalmologische Traumatologie*. Edited by Rohrbach JM, Steuhl K-P, Knorr M, Kirchhof B. Stuttgart: Schattauer Verlag; 2001: 170-177.
127. Luther T, **Thumann G**, Bartz-Schmidt KU: Posttraumatische Endophthalmitis. In: *Ophthalmologische Traumatologie*. Edited by Rohrbach JM, Steuhl K-P, Knorr M, Kirchhof B. Stuttgart: Schattauer Verlag; 2001: 309-316.
128. **Thumann G**, Hinton D: Biology of the retinal pigment epithelium. In: *Retina* (Third Edition). Edited by Ryan SJ, vol. 1. St Louis: Mosby; 2001: 104-121.
129. Bartz-Schmidt KU, Psichias A, **Thumann G**, Heimann K, Krieglstein G: Retinal Ischemia as a Risk Factor for Secondary Glaucoma and Its Clinical Consequences. In: *Pathogenesis and Risk Factors of Glaucoma*. Edited by Gramer E, Grehn F. Berlin Heidelberg: Springer-Verlag; 1999: 217-232.

130. Hlischneider A, Schweizer P, Vos A: Surgery for Liver Trauma. In: Hepatobiliary Surgery in Childhood. Edited by Schweizer P. Stuttgart: Schattauer verlag; 1991. Collaborating author: Thumann G.

Invited speaker (since 2013)

131. **Thumann, G**: Gene delivery using the non-viral Sleeping Beauty SB100X transposon system to treat retinal degeneration. 20th Congress of Croatian Ophthalmological and Optometric Society. May 14 to 17, 2020, Pula, Croatia.
132. **Thumann, G**: Gene Transfer to the eye using transposons. New Developments in Particles, Transfer Methods and Vectors for Gene Delivery symposium. 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT). May 12 to 15, 2020, Boston MA, USA.
133. **Thumann G**: Antibiotic-resistance-free Sleeping Beauty transposon plasmids to treat neovascular AMD - The TargetAMD Project. May 2018, Croatia.
134. **Thumann G**, TargetAMD consortium: Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration – a summary of the pre-clinical data. 25th European Society of Gene and Cell Therapy (ESGCT) and Deutsche Gesellschaft für Gentherapie (DG-GT) annual congress. Oct 17 to 20, 2017, Berlin, Germany.
135. **Thumann G**: Le projet européen TargetAMD – Thérapie Génique pour traiter la DMLA (Das EU Projekt TargetAMD – Eine Gentherapie zur Behandlung von AMD). 108th Congress of the Swiss Society of Ophthalmology (SSO-SGO). August 26 to 28, 2015, Fribourg, Switzerland.
136. **Thumann G**: Stammzelltherapie: Dr Jekyll oder Mr Hyde? 113th Annual Meeting of the Deutsche Ophthalmologische Gesellschaft. Oct, 2015, Berlin, Germany.
137. **Thumann G**: Retinal diseases – The importance of educated and active patients. World Health Organization (WHO). Oct, 2015, Geneva, Switzerland.
138. **Thumann G**: TargetAMD – Recherche européenne sur la Thérapie génique. Journée des ophtalmologues romands. Nov, 2015, Neuchâtel, Switzerland.
139. **Thumann G**: Future strategies to treat neurodegenerative diseases. Keynote lecture, European Society of ophthalmology (SOE), Jan 2015, Portoroz, Slovenia.
140. **Thumann G**: Gentherapie statt Avastin und Co. Innsbruck Medical School. Nov, 2014, Innsbruck, Austria.
141. **Thumann G**: Traitement des œdèmes maculaires par anti-VEGF. Continuous training, La Colline Clinic. Nov, 2014, Geneva, Switzerland.
142. **Thumann G**: Diabetic Retinopathy. United Nation Organization (UNO), Nov, 2014, Geneva, Switzerland.
143. **Thumann G**, Target AMD consortium: Transposon-based, targeted, ex-vivo gene therapy to treat age-related macular degeneration. Hum Gene Ther 2013, 24(12):A31. Meeting Abstract: Inv104.
144. **Thumann G**: Age-related macular degeneration, United Nation Organization (UNO). Oct, 2013, Geneva, Switzerland.
145. **Thumann G**: Non-viral gene therapy to treat ocular diseases, European Society of ophthalmology (SOE). Jun 2013, Copenhagen, Denmark.

Other articles, theses and proceedings

146. Kropp M, Harmening N, Conti A, Sealy G, Breuillard N, Mohit M, Maccari A, Bascuas-Castillo T, **Thumann G**: A transposon-based gene therapy approach to treat avascular Age-Related Macular Degeneration (AMD) using mRNA transposase: results of the *in vivo* local and systemic toxicity study. 29th annual Congress of the European Society of Gene and Cell Therapy (ESGCT), 11-14 Oct. 2022, Edinburgh, UK. Meeting abstract (submitted).
147. Maccari A, Kropp M, Harmening, Bascuas-Castillo, Breuillard N, Mohit M, Sealy G, **Thumann G**: Safety study for a non-viral gene therapy approach to treat dry AMD: *In vitro* exclusion of tumorigenicity of IPE cells transfected with the genes coding for PEDF and GM-CSF. 29th annual Congress of the European Society of Gene and Cell Therapy (ESGCT), 11-14 Oct. 2022, Edinburgh, UK. Meeting abstract (submitted).
148. Yüzgeç Ö, Gloria Y, Bayer L, Asadian A, Kropp M, **Thuman G**, Kecik, M, Maccari A, Schwartz S, Huber D. Pupil size indicates distinct brain states in human sleep. FENS Forum 2022, Paris, Fr. Meeting abstract, poster.
149. Breuillard N, Bascuas T, Harmening N, Sealy G, Mohit M, **Thumann G**, Kropp M: Efficiency analysis of a gene therapy approach for AMD in non-virally transfected IPE cells from human, pig and rabbit comparing long-term gene and protein expression. 115th Annual Meeting of SSO-SGO: 24 -26 Aug. 2022, Basel, Switzerland. Meeting abstract, poster: 8442.
150. Mohit M, Breuillard N, Harmening N, Bascuas T, Conti A, Sealy G, **Thumann G**, Kropp M: Up-scaling and humanization of retinal organotypic culture as a model for intraocular efficiency and toxicity analyses. ARVO annual meeting. 2022, Denver, USA / Virtual. Poster: 3161-F0435.

151. Breuillard N, Bascuas T, Harmening N, Sealy G, Mohit M, **Thumann G**, Kropp M: Comparison of long-term gene expression and protein secretion of non-virally transfected Retinal Pigment Epithelial (RPE) cells from human, pig and rabbit for preclinical efficiency analyses. ARVO annual meeting. 2022, Denver, USA / Virtual. Poster: 3173 – F0447.
152. **Thumann G**, Harmening N, Bascuas T, Breuillard N, Mohit M, Sealy G, Conti A, Kropp M: Safety and efficiency *in vitro* and *in vivo* data of non-virally transfected Pigment Epithelial cells using the Sleeping Beauty transposon system to treat age-related macular degeneration. XXXIIIrd Meeting of the Club Jules Gonin. 2022, Dubrovnik, Croatia. Meeting abstract, oral presentation.
153. Jukic T, Kecik M, Kropp M, Jonescu-Cuypers C, **Thumann G**: Anatomical and functional outcome in management of expulsive haemorrhage. XXXIIIrd Meeting of the Club Jules Gonin, 2022, Dubrovnik, Croatia. meeting abstract, poster.
154. **Thumann G**, Harmening N, Bascuas T, Breuillard N, Mohit M, Conti A, Kropp M: *In vivo* toxicity study in rabbits to prove tolerability of non-virally transfected Retinal (RPE) and Iris (IPE) Pigment Epithelial cells using the Sleeping Beauty transposon system to treat age-related macular degeneration. Retinal World Congress annual meeting. 2022, E-Live. E-poster.
155. Kropp M, **Thumann G**: Makuladegeneration. Online academy, editor: pnn pharma nation network ag. August, no FPH 2019, 72-01:1-10.
156. Kropp M, Tobalem S, Kecik M, Midroit M, Tardy S, Conti A, Harmening N, Bascuas T, Scapozza L, **Thumann G**: Improved transferability of a disease model for avascular age-related macular degeneration (AMD) to evaluate cell-based gene therapies using aged mice. Meeting Annual de l'International Society for Stem Cell Research (ISSCR), 2020, Boston, USA. Abstract: MDD228, p185.
157. Hernandez M, Recalde S, Garcia-Garcia L, Bezunartea J, Miskey C, Johnen S, Diarra S, Sebe A, Rodriguez-Madoz JR, Pouillot S, Marie C, Izsvák Z, Scherman D, Kropp M, Prosper F, **Thumann G**, Ivics Z, Garcia-Layana A, Fernandez-Robredo P: Cell-Based Gene Therapy Using the Sleeping Beauty Transposon System Reduces Neovascularisation in Rats. SSRN. 2019, June 2019:id3408024. Preprint of no. 18 of the list.
158. Kropp M, Ghezzi D, Conti A, Jonescu-Cuypers C, **Thumann G**: Surgical *in vivo* model in rabbits to test chronically self-opening intra-neural electrodes for optic nerve stimulation. Artificial Vision congress, Dec 2019, Aachen, Germany. DOI: 10.3205/19artvis24. Meeting abstract: Doc19artvis24. Oral presentation.
159. Verlooven R, Conti A, Harmening N, Bascuas T, **Thumann G**, Kropp M: Establishment of a xeno-free culture of retinal pigment epithelial (RPE) cells to produce personalized iPS-derived and genetically modified RPE cells to treat age-related macular degeneration (AMD). Symposium de l'International Society for Stem Cell Research (ISSCR) "From Stem Cell Biology to New Therapies" 2019, Toronto, Canada. Meeting Abstract.
160. Bascuas T, Harmening N, Kropp M, Sealy G, Conti A, Wong B, Zedira H, **Thumann G**: Non-virally transfected primary human pigment epithelium cells overexpressing the oxidative stress reduction factors PEDF and GM-CSF to treat retinal neurodegeneration. Hum Gene Ther 2019, 30(11):A112. Meeting Abstract: P318.
161. Harmening N, Wong BM, Sealy G, Bascuas T, Kropp M, Izsvák Z, **Thumann G**: Establishment of an *in vivo* protocol for non-viral gene delivery to ocular tissue. Hum Gene Ther 2019, 30(11):A112. Meeting Abstract: P317.
162. Kropp M, Zedira H, Conti A, Bascuas-Castillo T, Harmening N, **Thumann G**: *Ex vivo* efficacy study to evaluate neuroprotection in a retinal organotypic culture system: A gene therapeutic strategy to deliver growth factors to the retina to treat avascular age-related macular degeneration. Hum Gene Ther 2019, 30(11):A111. Meeting Abstract: P315.
163. **Thumann G**, Kropp M, TargetAMD consortium: tiPE - a GMP-Grade Non-Viral Gene Therapy Medicinal Product (GTMP) to Treat Neovascular Age-Related Macular Degeneration (nvAMD). Mol Ther 2019, 27(4):317. Meeting Abstract: #674.
164. Bascuas T, Kropp M, Harmening N, Tobalem S, Midroit M, Conti A, Asrih M, Sealy G, **Thumann G**: Non-viral transfections with the neuroprotective factors PEDF and GM-CSF reduces oxidative stress in human pigment epithelium cells *in vitro* offering a promising approach to treat avascular age-related macular degeneration. Hum Gene Ther 2018, 29(12):A88. Meeting Abstract: P205.
165. Cai H, Johnen S, Harmening N, Kropp M, Marie C, Scherman D, Ivics Z, **Thumann G**, Izsvák Z: While, no barrier insulator function is required for stable transgene expression from Sleeping Beauty transposon, 6CTCF enhancer blocker improves its biosafety for therapeutical applications. Hum Gene Ther 2018, 29(12):A161. Meeting Abstract: P468.
166. Johnen S, Harmening N, Kropp M, Castillo TB, Ronchetti M, Marie C, Scherman D, Ivics Z, Izsvák Z, Walter P, **Thumann G**: Genetic modification of freshly isolated primary human pigment epithelial cells to treat nvAMD. Hum Gene Ther 2018, 29(12):A91. Meeting Abstract: P216.

167. Kropp M, Harmening N, Bascuas T, Sealy G, Conti A, Johnen S, Izsvák Z, Marie C, Scherman D, Ronchetti M, Aranda P, Van den Berg J, **Thumann G**: GMP-grade production of tIPE, a cell-based gene therapy product to treat neovascular age-related macular degeneration (nvAMD) developed in the TargetAMD project. *Hum Gene Ther* 2018, 29(12):A69. Meeting Abstract: P142.
168. Kropp M, Harmening N, Kecik M, Chronopoulos A, Conti A, Bautzova T, **Thumann G**: Challenges in GTMP process validation for a non-viral gene therapy. *IOVS* 2018, 59(9). Meeting Abstract: 4543.
169. Fernandez P, Recalde S, Hernandez M, Garcia-Garcia L, Bezunartea J, Rodriguez JR, Marie C, Scherman D, Izsvák Z, Kropp M, Johnen S, **Thumann G**, Garcia-Layana A: Efficient choroidal neovascularization reduction by Sleeping Beauty Transposon-mediated PEDF gene delivery in rat iris and retinal pigment epithelial cells by using a clinical electroporator. *IOVS* 2018, 59(9). Abstract: 223.
170. Cai H, Szvetnik A, Garcia-Perez A, Adam L, Zhou Z, Wang J, Mermod N, **Thumann G**, Izsvák Z: Optimisation of Sleeping Beauty transposon system for gene therapy application to treat age-related macular degeneration (AMD). *Hum Gene Ther* 2017, 28(12):A121. Meeting Abstract: P359.
171. Diarra S, Waschkowski F, Moreno AG, Schiefer A, Lingg F, Izsvák Z, Ivics Z, **Thumann G**, Muller F, Mokwa W, Walter P, Johnen S: Efficient electrotransfer-mediated transfection of retinal pigment epithelial cells and retinas of the rd10 mouse model using the non-viral Sleeping Beauty transposon system. *Hum Gene Ther* 2017, 28(12):A120. Meeting Abstract: P376.
172. Diarra S, Waschkowski F, Moreno AG, Haselier C, Hesse S, Izsvák Z, Ivics Z, **Thumann G**, Muller F, Mokwa W, Johnen S, Walter P: Efficient electrotransfer-mediated transfection of rd10 retinas using the non-viral Sleeping Beauty transposon system. *IOVS* 2017, 58(8):3. Meeting Abstract: 4537.
173. Kropp M, Harmening N, Bautzova T, Asrih M, Sealy G, Johnen S, Izsvák Z, Marie C, Scherman D, Van den Berg J, **Thumann G**: Development of GMP-compliant production of freshly isolated and transfected iris pigment epithelial (IPE) cells to treat age-related macular degeneration (AMD). *Hum Gene Ther* 2017, 28(12):A118. Meeting Abstract: P371.
174. Johnen S, Diarra S, Harmening N, Marie C, Scherman D, Izsvák Z, Walter P, **Thumann G**: Genetic engineering of freshly isolated primary human pigment epithelial cells by non-viral gene delivery for the treatment of neovascular AMD. *IOVS* 2017, 58(8):3. Meeting Abstract: 4489.
175. Recalde S, Hernandez M, Fernandez P, Garcia-Garcia L, Rodriguez JR, Bezunartea J, Moreno M, Belza I, Marie C, Scherman D, Izsvák Z, Johnen S, **Thumann G**, Garcia-Layana A: Rat Primary Cells transfected with PEDF using the Sleeping Beauty Transposon system are effective in reducing the proangiogenic status in choroidal neovascularization. *IOVS* 2017, 58(8):4. Meeting Abstract: 1964.
176. Kropp M, Harmening N, Chronopoulos A, Conti A, Bautzová T, Weinberger A, Izsvák Z, Marie C, Scherman D, **Thumann G**: Process validation of a GMP-grade Advanced Therapy Medicinal Product for a Cell-Based Gene Therapy. *Congrès annuel de la SSO-SGO: 30 Aout – 02 Sept, 2017, Davos, Suisse*.
177. Kropp M, **Thumann G**: Gentherapie zur Behandlung der nAMD: das TargetAMD-Projekt. *Der Augenspiegel*. 2016, 1:50-52.
178. Diarra S, Plange N, Marie C, Scherman D, Izsvák Z, Ivics Z, Walter P, **Thumann G**, Johnen S: pFAR4/SB100X-mediated PEDF gene delivery in iris pigment epithelial cells isolated from patients' iridectomies mimicking a therapeutic approach for the treatment of neovascular AMD. *Hum Gene Ther* 2016, 27(11):A162. Meeting Abstract: P381.
179. Diarra S, Marie C, Scherman D, Izsvák Z, Miskey C, Sebe A, Ivics Z, Vereb Z, Walter P, **Thumann G**, Johnen S: Lack of indication for tumorigenicity after pFAR4/SB100X-mediated PEDF gene delivery in primary murine pigment epithelial cells ex vivo. *Hum Gene Ther* 2016, 27(11):A107. Abstract: P203.
180. Harmening N, Sealy G, Johnen S, Kropp M, Ronchetti M, Aranda P, Marie C, Scherman D, Izsvák Z, **Thumann G**: Translation of GLP-grade electroporation of primary pigment epithelial cells to GMP-grade GTMP manufacturing for clinical use. *Hum Gene Ther* 2016, 27(11):A108. Abstract: P207.
181. Johnen S, Diarra S, Harmening N, Marie C, Scherman D, Izsvák Z, Ivics Z, Walter P, **Thumann G**: pFAR4/SB100X-mediated PEDF gene delivery in primary human pigment epithelial cells for the treatment of neovascular AMD. *Hum Gene Ther* 2016, 27(11):A124. Meeting Abstract: P258.
182. Kropp M, Chronopoulos A, Conti A, Harmening N, Pouillot S, Izsvák Z, Marie C, Scherman D, **Thumann G**: Safety studies for cell-based gene therapy (TargetAMD project): *in vivo* exclusion of tumorigenicity and proof of cell product quality. *Hum Gene Ther* 2016, 27(11):A120. Meeting Abstract: P245.
183. **Thumann G**, Kropp M, Harmening N, Entire TargetAMD consortium: Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration: the TargetAMD project. *Hum Gene Ther* 2016, 27(11):A123. Meeting Abstract: P255.
184. Consigli A, Papanastasiou A, Roy S, **Thumann G**, Chronopoulos A: Intravitreal Aflibercept reduces the retinal vessel diameter in patients with diabetic macular edema. *IOVS* 2016, 57(12):2. Abstract: 2118.
185. Hernandez M, Garcia-Garcia L, Recalde S, Fernandez P, Rodriguez JR, Bezunartea-Bezunartea J, Scherman D, Johnen S, **Thumann G**, Garcia-Layana A: Efficacy of Rat Primary Cells transfected with Pigment Epithelium-Derived Factor using the Sleeping Beauty Transposon system in choroidal neovascularization. *IOVS* 2016, 57(12):3. Meeting Abstract: 271.

186. Kropp M, Chronopoulos A, Conti A, Harmening N, Pouillot S, Marie C, Scherman D, Izsvák Z, Aranda P, Fernandez V, **Thumann G**: Results of a biodistribution study of Venus transfected pigment epithelial cells transplanted subretinally in rabbits. IOVS 2016, 57(12):3. Meeting Abstract: 1187.
187. Prat-Souteyrand C, Harmening N, Kropp M, Sealy G, Izsvák Z, Scherman D, Marie C, Lohnen S, **Thumann G**: Human PEDF optimized gene for transposon-based gene therapy to treat age-related macular degeneration. IOVS 2016, 57(12):3. Meeting Abstract: 1172.
188. Recalde S, Jeanson-Leh L, Fernandez P, Hernandez M, Garcia-Garcia L, Bezunartea-Bezunartea J, Scherman D, Pouillot S, **Thumann G**, Garcia-Layana A: RT-qPCR quantification of mRNAs specific of Pigment Epithelium-Derived Factor (PEDF) and Vascular Endothelial Growth Factor (VEGF) in Rat eyes injected in the subretinal space with Primary Cells transfected with hPEDF. IOVS 2016, 57(12):3. Meeting Abstract: 281.
189. Harmening N, Sealy G, Kropp M, Marie C, Scherman D, Roncetti M, Aranda P, Fernandez V, Johnen S, Izsvák Z, **Thumann G**: Optimized Non-Viral Transfection of human RPE and IPE cells used for a Gene-Therapeutic Treatment of neovascular AMD. IOVS 2016, 56(7):3. Meeting Abstract: 4432.
190. **Thumann G**, Kropp M, Harmening N: Gentherapie statt Anti-VEGF bei AMD. Ophthalmologische Nachrichten 2015, 4:12.
191. Diarra S, Marie C, Scherman D, Izsvák Z, Ivics Z, Walter P, **Thumann G**, Johnen S: pFAR4/SB100X-mediated PEDF gene delivery in primary murine pigment epithelial cells. Hum Gene Ther 2015, 26(10):A46. Meeting Abstract: P066.
192. Kropp M, Tian S, Harmening N, Johnen S, Scherman D, Marie C, Izsvák Z, **Thumann G**: Over-expression of PEDF by PEDF-transfected primary pigment epithelial cells does not induce tumorigenicity. Hum Gene Ther 2015, 26(10):A81. Meeting Abstract: P184.
193. Prat-Souteyrand C, Tobalem S, Harmening N, Kropp M, Johnen S, Scherman D, Marie C, Izsvák Z, **Thumann G**: Stable genomic integration of PEDF in primary pigment epithelial cells transfected with the Sleeping Beauty transposon system to treat age-related macular degeneration (AMD). Hum Gene Ther 2015, 26(10):A80. Meeting Abstract: P182.
194. Dobias A, Marie C, Scherman D, Izsvák Z, Ivics Z, Walter P, **Thumann G**, Johnen S: Analysis of Potential Tumorigenicity of PEDF-Transfected Primary Human Retinal Pigment Epithelial Cells Using Soft Agar Assay. IOVS 2015, 56(7):2. Meeting Abstract: 2348.
195. Harmening N, Kropp M, Johnen S, Marie C, Scherman D, Izsvák Z, **Thumann G**: The use of mini-plasmids free of antibiotic resistance markers for a gene therapeutical approach to treat AMD. IOVS 2015, 56(7):3. Meeting Abstract: 2325.
196. Hernandez M, Garcia-Garcia L, Recalde S, Fernandez-Robredo P, Madoz JRR, Sherman D, Izsvák Z, Johnen S, **Thumann G**, Layana AG: Biodistribution of Rat Primary Cells transfected with SB100X transposon-mediated Pigment Epithelium-Derived Factor (PEDF) gene in Brown Norway rats after subretinal injection. IOVS 2015, 56(7):3. Meeting Abstract: 1835.
197. Kropp M, Harmening N, Johnen S, Tian SW, Scherman D, Marie C, Izsvák Z, **Thumann G**: pFAR4 miniplasmids in combination with the Sleeping Beauty transposon system allow efficient transfection of freshly isolated iris pigment epithelial cells. IOVS 2015, 56(7):3. Meeting Abstract: 2316.
198. **Thumann G**, Kropp M, Harmening N, TargetAMD consortium: Transposon-Based, Targeted Ex Vivo Gene Therapy to Treat Age-related Macular Degeneration. IOVS 2015, 56(7):2. Abstract: 1820.
199. Pastor M, Johnen S, Quiviger M, Izsvák Z, Scherman D, **Thumann G**, Marie C: Antibiotic-Free Nonviral pFAR4 Vector Displays Efficient Transgene Delivery in Mouse and Human Cells. Mol Ther 2015, 23:S228. Meeting Abstract: 572.
200. Scherman D, Pastor M, Marie C, Harmening N, Kropp M, Johnen S, Izsvák Z, **Thumann G**: The use of mini-plasmids free of antibiotic resistance markers for a gene therapeutical approach to treat AMD. 1st world Congress on Electroporation. 2015, Portoroz, Slovenia. Oral presentation.
201. Kropp M, Harmening N, Johnen S, Tian S, Scherman D, Marie C, Izsvák Z, **Thumann G**: Transfection of freshly isolated pigment epithelial cells with pFAR4 miniplasmids using the Sleeping Beauty (SB100X) transposon system. Hum Gene Ther 2014, 25(11):A106. Meeting Abstract: P156.
202. Garcia-Garcia L, Recalde S, Fernandez-Robredo P, Hernández M, Rodríguez JR, Bezunartea J, Marie C, Scherman D, Izsvák Z, Johnen S, **Thumann G**, Garcia-Layana A: Use of antibiotic-resistance-free plasmids for non-viral transfection of pigment epithelium-derived factor in rat primary cells. Acta Ophthalmol 2014, 92(s253):0. Meeting Abstract.
203. Pastor M, Johnen S, Quiviger M, Izsvák Z, Scherman D, **Thumann G**, Marie C: The Merging of the Antibiotic-Free pFAR4 Miniplasmids With the Sleeping Beauty Transposon System Mediates Higher Transgene Delivery in Human Cells. Mol Ther 2014, 22:S128. Meeting Abstract: 335.
204. Dobias A, Ronchetti M, Cadossi R, Walter P, **Thumann G**, Johnen S: Non-Viral Sleeping Beauty-Mediated Transfection of Retinal Pigment Epithelial Cells. IOVS 2014, 55(13):2. Meeting Abstract: 1827.
205. Kürten D, Johnen S, **Thumann G**: Transplantation of PEDF-Transfected Pigment Epithelial Cells Inhibits Corneal Neovascularization in a Rabbit Model. IOVS 2014, 55(13):3. Meeting Abstract: 3250.
206. Thies J, Gillissen M, Koroniak L, Mihov G, Kropp M, **Thumann G**: Slow-release latanoprost delivery by DSM's injectable PEA microfibers. IOVS 2014, 55(13):3. Meeting Abstract: 5256.

207. **Thumann G**, Marie C, Izsvák Z, Scherman D, Walter P, Johnen S: The Use of Plasmids Free of Antibiotic Resistance Markers for Safe and Efficient Sleeping Beauty-Mediated PEDF Gene Delivery into Primary Pigment Epithelial Cells. IOVS 2014, 55(13):3. Meeting Abstract: 1826.
208. Thumann G, Marie C, Izsvák Z, Scherman D, Harmening N, Kropp M, Johnen S: Safety Strategies in Transposon-Based Plasmids for Gene Therapy. XXIXth Meeting of the Club Jules Gonin. 2014, Zürich, CH. Présentation orale.
209. Harmening N, Johnen S, Izsvák Z, Kropp M, Diarra S, **Thumann G**: Use of Sleeping Beauty transposase mRNA for safe and efficient gene delivery in pigment epithelial cells. Hum Gene Ther 2013, 24(12):A59. Meeting Abstract: P001.
210. Johnen S, Marie C, Izsvák Z, Harmening N, Scherman D, Walter P, **Thumann G**: Efficient Sleeping Beauty-mediated transposition of primary pigment epithelial cells with PEDF delivered by plasmids free of antibiotic resistance markers (pFARs). Hum Gene Ther 2013, 24(12):A139. Abstract: P281.
211. Pastor M, Johnen S, Quiviger M, Izsvák Z, Scherman D, **Thumann G**, Marie C: The merging of the antibiotic-free pFAR4 miniplasmids with the Sleeping Beauty transposon system mediates higher transgene delivery in human cells. Hum Gene Ther 2013, 24(12):A61. Meeting Abstract: P008.
212. **Thumann G**, Mihov G, Thies J, Kemp A, Morawa K, Kropp M: Slow-release intraocular drug delivery by injectable PEA microfibrils (DSM, NL). IOVS 2013, 54(15):2. Meeting Abstract: 5045.
213. Baltz T, Haselier C, Hesse S, Meißner F, Endler I, Walter P, **Thumann G**: Effect of Multi-walled Carbon Nanotubes on R28 retinal precursor Cell Survival. IOVS 2012, 53(14). Meeting Abstract: 336.
214. **Thumann G**, Harmening N, Dobias A, Johnen S: Efficient Transfection and Genomic Integration of the PEDF Gene into a Limited Number of Primary IPE Cells. IOVS 2012, 53(14). Meeting Abstract: 5847.
215. Röpke AK, Johnen S, Fuest M, Walter P, **Thumann G**: Genomic Stability in Sleeping Beauty transposon-mediated transfection of RPE cells with the gene for PEDF. IOVS 2012, 53(14). Meeting Abstract: 5309.
216. Siapich S, Hartleb M, Schneider T, **Thumann G**, Walter P: Effects of Ethambutol on the ERG a-Wave Amplitude From the Isolated Superfused Vertebrate Retina. IOVS 2012, 53(14). Meeting Abstract: 5368.
217. Rieck AC, Salz AK, Johnen S, Walter P, Thumann G: Bovine Collagen as a Substratum for Subretinal Transplantation of Pigment Epithelial Cells. IOVS 2012, 53(14). Meeting Abstract: 6563.
218. Johnen S, Izsvák Z, Walter P, **Thumann G**: Efficient transfection of 10'000 pigment epithelial cells with PEDF using the Sleeping Beauty transposon system. Hum Gene Ther 2012, 23(10):A81. Abstract.
219. Dobias A, Salz AK, Walter P, **Thumann G**: Phagocytic Activity of ARPE-19 Cells on Biological and Artificial Substrata. IOVS 2010, 51(13):2. Meeting Abstract: 336.
220. Johnen S, Stöcker M, Walter P, **Thumann G**: Long Term Expression of rPEDF in Primary Pigment Epithelial Cells After Non-Viral Transfection With Linearized Plasmids. IOVS 2010, 51(13):2. Abstract: 5255.
221. Kazanskaya O, Möller T, **Thumann G**: Recombinant PEDF Proteins Produced in Eucaryotic Cells: Potential Use for Anti-Angiogenic Therapy of AMD. IOVS 2010, 51(13):2. Meeting Abstract: 4754.
222. Koutsonas A, Kazanskaya O, Bozlu L, Walter P, **Thumann G**: The Effect of High Glucose on Retinal Cells in an Organotypic Retina Culture Model. IOVS 2010, 51(13):2. Meeting Abstract: 5598.
223. Stickelmann C, Dobias A, Johnen S, **Thumann G**: Efficient Genetic Modification of Very Low Numbers of Pigment Epithelial Cells by Non-Viral Transfection Protocols. IOVS 2010, 51(13):2. Abstract: 4501.
224. **Thumann G**, Tholl S, Sellhaus B, Walter P, Salz AK: Comparison of Ultrathin Bovine Collagen Membranes and Human Amniotic Membranes for Ocular Applications. IOVS 2010, 51(13):2. Abstract: 5250.
225. Vehr A, Johnen S, Wickert L, **Thumann G**: Genomic Stability in Established RPE Transfectants. IOVS 2010, 51(13):3. Meeting Abstract: 4098.
226. **Thumann G**, Maltusch C, Stöcker M, Salz AK, Walter P, Johnen S: Efficient Non-Viral Transfection of Primary Pigment Epithelial Cells With Human PEDF. IOVS 2009, 50(13). Meeting Abstract: 6231.
227. Chankiewicz E, Bachmann B, Blazejewska E, Schloetzer-Schrehardt U, **Thumann G**, Rummelt C, Kruse F: A Novel Ultrathin Collagen Membrane for ex-vivo Expansion and Transplantation of Corneal Epithelial Cell Sheets. IOVS 2009, 50(13). Meeting Abstract: 1521.
228. Salz AK, Maltusch C, Peters E, Rieck AC, Gaebler A, Johnen S, Walz A, Walter P, **Thumann G**: Growth of IPE and RPE Cells on Biological and Artificial Substrata. IOVS 2009, 50(13). Meeting Abstract: 1835.
229. Johnen S, Maltusch C, Stöcker M, Wickert L, Salz AK, Walter P, **Thumann G**: Effect of PEDF Fusion Proteins on the Expression of Zinc Transporter Proteins. IOVS 2009, 50(13). Meeting Abstract: 2164.
230. Roessler GF, Kaempf S, Klee D, Mokwa W, Koch C, Sellhaus B, Mazinani B, **Thumann G**, Walter P: Muller Cell Culture *in-vitro* Experiments of Biochemically Modified Surfaces as a Fixation Concept for Epiretinal Stimulator Arrays. IOVS 2009, 50(13). Meeting Abstract: 4597.
231. Salz AK, Kaempf S, Johnen S, Maltusch C, Lindt R, Walter P, **Thumann G**: Tissue Engineering of Cell Monolayers for Subretinal Transplantation. IOVS 2008, 49(13). Meeting Abstract: 279.
232. Maltusch C, Johnen S, Wickert L, Kaempf S, Salz AK, Walter P, **Thumann G**: 3T3 Feeder Cells Highly Improve Efficiency of Primary Pigment Cell Cultures. IOVS 2008, 49(13). Meeting Abstract: 3869.
233. Lindt R, Johnen S, Kaempf S, Salz AK, Walter P, **Thumann G**: High Efficiency Non-Viral Transfection of IPE and RPE Cells by Electroporation. IOVS 2008, 49(13). Meeting Abstract: 3870.

234. **Thumann G**, Kaempf S, Salz AK, Perera D, Johnen S, Maltusch C, Walter P: Biocompatibility of Collagen Type 1 Scaffolds for Subretinal Transplantation. IOVS 2008, 49(13). Meeting Abstract: 4047.
235. Steinfeld PA, Dahlmann R, Mazinani B, Kaempf S, Walter P, **Thumann G**: IOL Opacification Following Retinal Surgery Combined With Intraocular Silicone Oil Endotamponade. IOVS 2008, 49(13). Meeting Abstract: 5960.
236. Kaempf S, Johnen S, Salz AK, Maltusch C, Lindt R, Walter P, **Thumann G**: Retinal Toxicity of Bevacizumab (Avastin) in Organotypic Culture. IOVS 2008, 49(13). Meeting Abstract: 5570.
237. **Thumann G**, Kaempf S, Salz A, Viethen A, Kreuzer J, Heschel I, Walter P: Tissue-Engineered Biodegradable Pigment Epithelial Cell Sheets for Transplantation to the Subretinal Space. IOVS 2007, 48(13). Meeting Abstract: 5086.
238. **Thumann G**, Aisenbrey S, Walter P, Bartz-Schmidt KU: Long-Term Functional Results Following 360 Macular Rotation. IOVS 2006, 47(13). Meeting Abstract: 1435.
239. **Thumann G**: Long-term preservation of photoreceptors in RCS rats by transplantation of homologous and heterologous IPE cells. IOVS 2005, 46(13):1. Meeting Abstract: 4159.
240. Welsandt GR, Hueber A, **Thumann G**: Influence of extracellular membrane proteins on RPE functions. IOVS 2005, 46(13):1. Meeting Abstract: 3037.
241. **Thumann G**, Hueber A, Schaefer F, Kirchhof B: Biological characteristics of pigment epithelial cells on a collagen foil. IOVS 2004, 45(13):U67. Meeting Abstract: 3108.
242. **Thumann G**, Schaefer F, Theofylaktopoulos I, Kirchhof B: Transplantation to the subretinal space of pigment epithelial cells cultured on ultrathin collagen sheets. IOVS 2003, 44(13):U98. Abstract: 491.
243. Aisenbrey S, **Thumann G**, Lafaut BA, Walter P, Esser P, Farvili E, Kirchhof B, Bartz-Schmidt KU: Transplantation of iris pigment epithelial cells to the subretinal space in exudative macular degeneration: A three year follow-up. IOVS 2002, 43(13):U974. Meeting Abstract: 3453.
244. Kociok N, Schraermeyer U, Luther TT, **Thumann G**, Jordan JF, Esser P, Kirchhof B: Identification of differentially expressed genes in RPE cells of dystrophic RCS rats with possible connection to age-related macular degeneration in man. IOVS 2002 43(Suppl. 2):U654. Meeting Abstract: 2806.
245. Omran M, Kirchhof B, **Thumann G**: Suspension culture of RPE and IPE cells. IOVS 2002, 43:U152. Meeting Abstract: 707.
246. Roters S, Hamzei P, Szurman P, **Thumann G**, Bartz-Schmidt KU, Kirchhof B: One-year outcome of penetrating keratoplasty after combined vitreoretinal surgery with silicone oil. IOVS 2002, 43:U138. Meeting Abstract: 638.
247. **Thumann G**, Schaefer F, Finkam J, Aisenbrey S, Kociok N, Kirchhof B: Growth of iris pigment epithelial cells on a biodegradable substratum. IOVS 2002, 43:U974. Meeting Abstract: 3454.
248. Aisenbrey S, Lafaut BA, **Thumann G**, Grisanti S, Szurman P, Walter P, Bartz-Schmidt KU: Pathologic features of radiation-associated choroidal neovascuopathy. IOVS 2001, 42(4):S226. Abstract.
249. Kociok N, Hueber A, Esser P, **Thumann G**, Luther T, Welsandt G, Jordan J, Krott R, Kirchhof B, Schraermeyer U: Vitreous treatment of cultured human RPE cells result in differential expression of ten new genes. IOVS 2001, 42(4):S810. Meeting Abstract.
250. **Thumann G**, Aisenbrey S, Kociok N, Schraermeyer U, Esser P, Bartz-Schmidt KU, Walter P, Kirchhof B: Promotion of Retinal pigment epithelial cell characteristics in Iris pigment epithelial cells cultured on a feeder cell layer. IOVS 2001, 42(4):S758. Meeting Abstract.
251. Dintelmann TS, **Thumann G**, Bartz-Schmidt KU, Schraermeyer U: Human iris pigment epithelial cell culture from iridectomy specimen. IOVS 2000, 41(4):S852. Meeting Abstract.
252. Kayatz P, **Thumann G**, Krott R, Bartz-Schmidt KU, Schraermeyer U: Autofluorescence of melanin after exposure to oxidative stress. IOVS 2000, 41(4):S415. Meeting Abstract.
253. Roters S, **Thumann G**, Kayatz P, Bartz-Schmidt KU, Schraermeyer U: Correlation of fundoscopic findings with their ultrastructure in early age-related macular degeneration. IOVS 2000, 41(4):S160. Abstract.
254. Schraermeyer U, Kociok N, **Thumann G**, Kayatz P, Bartz-Schmidt KU: Isolation of RPE cell sheets of high purity and viability from young and adult eyes by a simple method. IOVS 2000, 41(4):S857. Abstract.
255. Szurman P, **Thumann G**, Schraermeyer U, Bartz-Schmidt KU: Modification of retinal adhesion for macular translocation - ultrastructural findings after artificial retinal detachment. IOVS 2000, 41(4):S181. Meeting Abstract.
256. **Thumann G**, Kayatz P, Bartz-Schmidt KU, Schraermeyer U: Blocking of lysosomal degradation inhibits fluid flow through Bruch's membrane and choriocapillaris. IOVS 2000, 41(4):S116. Meeting Abstract.
257. Aisenbrey S, **Thumann G**, Jonescu-Cuypers C, Bartz-Schmidt KU: Quantitative morphological and functional evaluation of the optic nerve head in glaucoma. IOVS 1999, 40(4):S80. Meeting Abstract.
258. Bartz-Schmidt KU, **Thumann G**, Kociok N, Esser P, Heimann K, Schraermeyer U: Detection of mRNA for proteins involved in retinol metabolism in iris pigment epithelium. IOVS 1999, 40(4):S218. Abstract.
259. Bieker A, Kayatz P, **Thumann G**, Heimann K, Schraermeyer U: RPE cells and uveal melanocytes of albino rats take up subretinal injected melanin, thus resembling wild-type cells. IOVS 1999, 40(4):S182. Meeting Abstract.
260. Eichholtz C, Esser P, Heimann K, Schraermeyer U, **Thumann G**, Martiny B, Weller M: FAS/APO-1-mediated apoptosis in lens epithelial cells. Modulation by cytokines. IOVS 1997, 38(4). Abstract: 205.

261. Baum UE, **Thumann G**, Bartz-Schmidt KU, Luke C, Walter P, Esser P, Heimann K: *In vitro* dose response effects of etoposide on cultured human RPE. IOVS 1997, 38(4). Meeting Abstract: 916.
262. **Thumann G**, Heimann K, Schraermeyer U: Quantitative phagocytosis of rod outer segments by human and porcine iris pigment epithelial cells *in vitro*. IOVS 1997, 38(4). Meeting Abstract: 1542.
263. Baum UE, Hueber A, **Thumann G**, Esser P, Bartz-Schmidt KU, Heimann K: Total vitreous protein concentration and clinical course of proliferative vitreoretinal disorders. Vision Res 1996, 36(Suppl. S):416. Meeting Abstract.
264. Grundler AE, Bartz-Schmidt KU, Jonescu-Cuypers CP, **Thumann G**, Jonas JB: The cumulative rim/disc area ratio curve of normal eyes using standard optic disc photographs. Vision Res 1996, 36(Suppl. S):2113. Meeting Abstract.
265. **Thumann G**, Schraermeyer U, Heimann K: Descemet's membrane as an autologous collagen support in RPE/IPE transplantation. IOVS 1996, 37(3). Meeting Abstract: 466.
266. Baum U, Hueber A, **Thumann G**, Esser P, Heimann K: Total protein concentration of vitreous and clinical course of proliferative vitreoretinal diseases. IOVS 1996, 37(3). Meeting Abstract: 1811.
267. **Thumann G**, Rezaei AK, Lappas A, Heimann K: Comparison of tight junction permeability and modulation in iris pigment-epithelium and retinal-pigment epithelium *in vitro*. Vision Res 1995, 35:P419. Meeting Abstract.
268. Lappas A, Rezaei KA, **Thumann G**, Heimann K: Vital assay of phagocytosis by human iris pigment-epithelium and retinal-pigment epithelium. IOVS 1995, 36(4):S550. Meeting Abstract.

DATE AND SIGNATURE: October 19, 2022



¹ : Thumann G. belongs to the "BONSAI" study group (Brain and Optic Nerve Study with Artificial Intelligence).

²: Thumann G. belongs to the "Grand Challenges in Global Eye Health" study group.

* : These authors contributed equally to the publication.